www.imuc.com
ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat different cancers.
Related Media
Archive-
01/08/2011
Manish Singh, President & CEO of ImmunoCellular Therapeutics, talks about targeting cancer stem cells
Manish Singh, President & CEO of ImmunoCellular Therapeutics, talks about targeting cancer stem cells – which are like the roots of cancers, 40% of glioblastoma patients (from a Phase 1 trial) being cancer free after 3-4 years & a platform for delivering cancer stem cell antigens for multiple different indications (July 2011).
What do others think of ImmunoCellular Therapeutics
Presentations & Company Media
01/02/2012
ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference (Presentation)08/06/2011
Fact Sheet Q2 2011 (Presentation)08/06/2011
Dawson James Securities Report (Presentation)01/05/2011
ImmunoCellular Therapeutics Presentation - May 2011 (Presentation)
Related Research & Media
01/02/2012
Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach (Presentation)01/02/2012
Immunocellular: Pipeline Potential And Institutional Interest Fuel Rebound (Presentation)27/01/2012
Pharma Leaders Emerging In Immunotherapy Approach To Fighting Glioblastoma (Presentation)08/11/2011
ImmunoCellular's ICT-107 Touted As A Stand Out Therapeutic Vaccine (Presentation)08/06/2011
Dawson James Securities Report (Presentation)
Company Statement:
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer. Our products and technologies are designed to harness the power of the immune system to improve the treatment and diagnosis of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our most advanced clinical program, ICT-107 is currently in phase II trial for glioblastoma multiforme, the most aggressive brain cancer. This technology platform has potential applications in many other solid cancers such as ovarian and pancreatic cancers.
Management
Manish Singh, Ph.D., MBA, President and Chief Executive Officer
John S. Yu, M.D., Chief Scientific Officer and Chairman of the Board
David Fractor, Chief Financial Officer
James G. Bender, Ph.D., M.P.H., Vice President, Clinical Development
Major Shareholders
No info available.
Contact Information
ImmunoCellular Therapeutics, Ltd
21900 Burbank Blvd, 3rd Floor
Woodland Hills, CA 91367
Tel: (818) 992-2907
Fax: (818) 992-2908
Email: info@imuc.com
Investor Relations
James Young, CEOcast, Inc.
Investor Relations
Tel: (212) 732-4300
Email: IR@imuc.com
Media Contact
Meghan Feeks
(508) 274-1127
Email: meghan.feeks@imuc.com
Corporate Information
No info available.
